MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

OPTI-ON: A Longitudinal Real-World Study of Opicapone in Patients with Parkinson’s Disease and Motor Fluctuations

P. Lewitt, O. Klepitskaya, L. Bahroo, G. Liang, S. Rattana, J. Trotter, M. Serbin (West Bloomfield, USA)

Meeting: MDS Virtual Congress 2021

Abstract Number: 410

Keywords: Parkinson’s

Category: Parkinson’s Disease: Clinical Trials

Objective: To conduct a longitudinal real-world study that examines treatment patterns, clinical outcomes, safety and tolerability of opicapone as an adjunctive treatment to carbidopa/levodopa (CD/LD) in patients with Parkinson’s disease (PD) who are experiencing OFF-episodes.

Background: Motor fluctuations and wearing-off of medications are common complications as PD progresses. Opicapone is an oral once-daily catechol-O-methyltransferase (COMT) inhibitor for adjunctive treatment to CD/LD in patients with PD and OFF-episodes. The efficacy and safety of opicapone was demonstrated in two phase 3 studies that were conducted in Europe and Asia (BIPARK-1, BIPARK-2). An observational phase 4 study in the United States (US), OPTI-ON (Opicapone Treatment Initiation Open-Label Study [NCT04787965]), is currently underway.

Method: OPTI-ON is an ongoing, prospective, multicenter, open-label study of opicapone as an adjunctive treatment to CD/LD. Approximately 250 clinically eligible patients with PD and OFF-episodes are being enrolled at about 50 sites in the US. Participation in the study is expected to continue for up to 6 months. Assessments include patient demographics and clinical history, opicapone treatment decisions (reasons for initiation or discontinuation), use of other PD medications, and changes in PD medications. Clinician- and patient-rated outcomes (PROs) include: Clinician Global Impression of Change; MDS-Unified Parkinson’s Disease Rating Scale, Parts 1A and 4 (clinician), Parts 1B and 2 (patient); Patient Global Impression of Change; Patient Global Impression of Severity in ON- and OFF-states; and 8-item Parkinson’s Disease Questionnaire. This is also the first longitudinal study to implement the new clinician- and patient-rated Non-Motor Fluctuation Assessment. Assessments are completed online by patients (electronic PROs) and performed by clinicians during office visits or via telemedicine.

Results: Up-to-date findings will be presented.

Conclusion: Results from the OPTI-ON study are expected to provide real-world information about the patterns of use and outcomes with adjunctive opicapone for treatment of PD in clinical practices throughout the US. These results will expand upon findings from the phase 3 clinical trials, which established the efficacy and safety of once-daily opicapone in patients with PD and OFF-episodes.

To cite this abstract in AMA style:

P. Lewitt, O. Klepitskaya, L. Bahroo, G. Liang, S. Rattana, J. Trotter, M. Serbin. OPTI-ON: A Longitudinal Real-World Study of Opicapone in Patients with Parkinson’s Disease and Motor Fluctuations [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/opti-on-a-longitudinal-real-world-study-of-opicapone-in-patients-with-parkinsons-disease-and-motor-fluctuations/. Accessed July 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/opti-on-a-longitudinal-real-world-study-of-opicapone-in-patients-with-parkinsons-disease-and-motor-fluctuations/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #25676 (not found)
  • Crack Dancing: An Uncommon Drug-Induced Chorea
  • #24376 (not found)
  • An atypical and interesting feature of Parkinson´s disease
  • A Case of Pregabalin induced Parkinsonism
  • A survey-based analysis of abnormal movements in patients with Postural Tachycardia Syndrome (PoTS)
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley